FDA Authorizes Monoclonal Antibodies to Prevent COVID-19

12/15/21 — FDA issued an EUA for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the prevention of COVID-19 in certain adults and children. Although vaccines have proven to be the best defense against COVID-19, some people may not have an adequate immune response or have a history of severe adverse reactions to the vaccine. This product is only authorized for individuals who are not currently infected or recently been exposed to someone infected with the SARS-CoV-2 virus who have either:

• Moderately to severely compromised immune systems due to a medical condition or immunosuppressive medications; or
• A history of severe adverse reactions to a COVID-19 vaccine or components of the vaccines, so vaccination with an available COVID-19 vaccine is not recommended.

Read the FDA announcement and fact sheets for healthcare providers and patients and caregivers.